Our History
Since 1999, our non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects.
As advanced therapeutic modalities move from concept to clinic, new cell engineering approaches will emerge and mature. MaxCyte will continue to leverage our best-in-class electroporation technology and experience in the industry to support our partners in pushing the frontiers of bio-based medicines.
A history of innovation driving cell engineering-based therapeutics
1999
Founding
Doug Doerfler and Doctors Joseph Fratantoni and John Holaday started MaxCyte to commercialize flow electroporation technology.
2000
Launch—MaxCyte GT® scalable transfection system
To overcome transfection challenges and enable cell therapy development and commercialization, we launched our first flow electroporation instrument, the MaxCyte GT Scalable Transfection System.
2003
First licensing agreements
We began licensing our flow electroporation technology to companies developing human cell therapies, recognizing that our electroporation and cell engineering expertise was essential for partner success.
2003
Launch—MaxCyte STX™ scalable transfection system
The development and launch of the MaxCyte STX Scalable Transfection System brought our powerful technology to the burgeoning areas of cell-based assays for high-throughput and high-content screening and preclinical protein production.
2013
Joint collaboration and publication
“Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL”
Wolfraim LA, et al. Int Immunopharmacol. 2013 Mar;15(3):488-97. doi: 10.1016/j.intimp.2013.01.009.
2019
Launch—ExPERT™ platform
We brought a family of instruments—the ATx, STx and GTx systems—to the market as the next generation of clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, MaxCyte continued its uncompromising focus on high performance cell engineering, while delivering feature enhancements that enabled customers to use a single unifying technology, from concept to commercialization.
2021
Initial public offering
After decades of hard work and technical innovation, we became a publicly traded company listed on NASDAQ.
2022
Launch—VLx™ system
We continue to advance our delivery technology with the VLx System, which revolutionizes protein production with true scalability.
